| Background: Mycobacterium wis an immunomodulatorthat evokes antigen-specific cell-mediated immunity and its use has been evaluated in patients with sepsis, where it resulted in improved outcome. Methods: We collected data in ten adult patientswith suspected gram-negative sepsis admitted inthe intensive care unit. Injection Mw 0.3 ml was administered intradermal per day for three consecutive days alongwith continuation of standard care. Results: We observed clinical improvement and a significant decrease in TLC and SOFA Score on day 7 after Mw administration. Also, Mw was not associated with any local or systemic adverse effects. Conclusion: The use of Mw was safe and effective in patients with sepsis, though larger randomized trials are required to establish its role. | 
 Download PDF
 Download PDF
     Download PDF
 Download PDF
     Download PDF
 Download PDF
     Download PDF
 Download PDF
     +91 9063922599
                            +91 9063922599
                         +91 9063922599
                            +91 9063922599
                         editor@healthcare-bulletin.co.uk
                            editor@healthcare-bulletin.co.uk